Long-term cardiotoxicity outcomes of trastuzumab and cardiac safety of novel HER2-targeted therapies.

Esen SA, Uncu D, Sendur MAN

DOI: 10.1080/14740338.2026.2667402
Published: 2026 May 4
Container: Expert opinion on drug safety
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14740338.2026.2667402,
  title = {Long-term cardiotoxicity outcomes of trastuzumab and cardiac safety of novel HER2-targeted therapies.},
  author = {Esen SA and Uncu D and Sendur MAN},
  year = {2026},
  journal = {Expert opinion on drug safety},
  doi = {10.1080/14740338.2026.2667402},
  url = {https://doi.org/10.1080/14740338.2026.2667402}
}

RIS

TY  - JOUR
TI  - Long-term cardiotoxicity outcomes of trastuzumab and cardiac safety of novel HER2-targeted therapies.
AU  - Esen SA
AU  - Uncu D
AU  - Sendur MAN
PY  - 2026
JO  - Expert opinion on drug safety
DO  - 10.1080/14740338.2026.2667402
UR  - https://doi.org/10.1080/14740338.2026.2667402
ER  -

APA

SA, E., D, U., & MAN, S. (2026). Long-term cardiotoxicity outcomes of trastuzumab and cardiac safety of novel HER2-targeted therapies.. Expert opinion on drug safety. https://doi.org/10.1080/14740338.2026.2667402

Source records

pubmed · retrieved 2026-11-11T00:02:44.946Z